Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01266096 · ClinicalTrials.gov registry record · NA
PET Imaging of Patients With Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing Study
A NA study of Malignant Brain Tumors and Newly Diagnosed or Recurrent Metastatic Melanoma Patients, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT01266096 is a NA study of Malignant Brain Tumors and Newly Diagnosed or Recurrent Metastatic Melanoma Patients that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 10 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01266096, a NA study of Malignant Brain Tumors and Newly Diagnosed or Recurrent Metastatic Melanoma Patients, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
Current tests to detect cancer, including CAT scans and MRI scans, are limited. PET scans use special dyes that are injected into a vein and can better localize possible cancer. The investigators have developed a new particle that can carry a radioactive dye to a very specific area of the tumor. When using a PET scan the radioactive dye can be viewed in areas of possible disease. This particle has been studied in mice and was safe. The particles will not treat the cancer and any images or information found during this study will not be used for your treatment. The information collected may be used to guide the design of future studies to detect and/or treat tumors.
Conditions Studied
Interventions
- DRUG PET scan with 124I-cRGDY-PEG-dots
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2011-01 |
| Est. Completion | 2026-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01266096
The ClinicalTrials.gov registry entry for NCT01266096 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Malignant Brain Tumors appearing as the primary indexed condition, and to 1 intervention - of which PET scan with 124I-cRGDY-PEG-dots is the first listed.
NCT01266096 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01266096 about?
NCT01266096 is a clinical study titled "PET Imaging of Patients With Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing Study". Current tests to detect cancer, including CAT scans and MRI scans, are limited. PET scans use special dyes that are injected into a vein and can better localize possible cancer. The investigators have developed a new particle that can carry a radioactive dye to a very specific area of the tumor. Whe...
What is the current status of trial NCT01266096?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 10 participants. The study started on 2011-01. Estimated completion is 2026-12.
What conditions does trial NCT01266096 study?
This clinical trial studies the following conditions: Malignant Brain Tumors, Newly Diagnosed or Recurrent Metastatic Melanoma Patients.
What interventions are being tested in trial NCT01266096?
The interventions under investigation include: PET scan with 124I-cRGDY-PEG-dots (DRUG).
Who is sponsoring clinical trial NCT01266096?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01266096 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Brain Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Malignant Brain Tumors
All registered trials for this condition
Newly Diagnosed or Recurrent Metastatic Melanoma Patients
All registered trials for this condition
New York
All trials with a study site in New York
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.